Nov 08, 2021
Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer
Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details
Nov 02, 2021
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent
Oct 28, 2021
Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III
Oct 27, 2021
Immutep Quarterly Activities Report
